近日，中国证券监督管理委员会贵州监管局(以下简称贵州证监局)对贵州百灵企业集团制药股份有限公 司(以下简称贵州百灵)涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 财务造假是严重破坏市场"三公"原则，侵害投资者合法权益的毒瘤。贵州证监局将坚决贯彻证监会党委 的各项决策部署，着力提升监管执法的有效性和震慑力，坚持对财务造假"零容忍"打击的鲜明立场，聚 焦打大、打恶、打重点，紧盯实控人、控股股东、董事、高管等"关键少数"和中介机构"看门人"，严格 执法、秉公执法，坚决做到监管"长牙带刺"、有棱有角，以有力监管执法护航贵州资本市场行稳致远。 来源｜证监会网站 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至 2021年期间少计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万 元。对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正， 给予警告，处以1000万元罚款;拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜 伟采取10年证券市场禁入措施。 ...

12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限公司(以 下简称"贵州百灵")涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 贵州百灵股票自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。自2025年12月23日开 市起，贵州百灵股票简称由"贵州百灵"变更为"ST百灵"，股票代码不变，仍为"002424"，股票交易日涨 跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 （文章来源：21世纪经济报道） 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至 2021年期间少计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万 元。 对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正，给予 警告，处以1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采 取10年证券市场禁入措施。 同日，苗药龙头股贵州百灵发布公告， ...

12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵（002424）企业集团制药股份有限公司(以下 简称"贵州百灵")涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至2021年期间少 计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万元。 对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正，给予警告，处以 1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证券市场禁入措 施。 同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处罚事先告知书》，因贵 州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。自2025年12月23日开市起，贵州百 灵股票简称由"贵州百灵"变更为"ST百灵"， ...

Core Viewpoint - Three A-share listed companies received administrative penalty notices from regulatory authorities for financial fraud, raising market concerns [1] Group 1: Guizhou Bailin - Guizhou Bailin reported false records in its annual reports for 2019, 2020, 2021, and 2023, leading to a warning and a change in stock designation to "ST Bailin" with a trading limit of 5% [2] - The company was found to have understated sales expenses, resulting in an inflated profit of 654.726 million yuan from 2019 to 2021, and overstated sales expenses in 2023, reducing profit by 459.411 million yuan [2] - Guizhou Securities Regulatory Bureau proposed a fine of 10 million yuan for the company and a total of 15.6 million yuan for 10 responsible individuals, with a 10-year market ban for one individual [2] Group 2: Funu Dongfang - Funu Dongfang received an administrative penalty notice for false records in its annual reports for 2020 and 2021 [5] - The company was involved in a scheme that inflated profits by 35.798 million yuan in 2020, which was 120.18% of the reported profit, and reduced profits by 22.651 million yuan in 2021, accounting for 6.64% of the reported profit [6] - The stock designation will change to "ST Funu" with a trading halt for one day starting December 22, 2025 [7] Group 3: ST Yuanzhi - ST Yuanzhi was penalized for false records in its annual reports from 2019 to 2022, with a fine of 6 million yuan imposed [10] - The company falsely recognized sales revenue from elevator sales using forged acceptance certificates, inflating revenue by 123.238 million yuan in 2019, 66.226 million yuan in 2020, and 138.250 million yuan in 2021 [11] - The company also inflated revenue by 9.148 million yuan in 2021 from a lease agreement that was never executed, leading to a profit inflation of 8.482 million yuan, which was 62.47% of the reported profit [12]

Group 1 - The core issue involves Guizhou Bailing's financial fraud, leading to administrative penalties from the Guizhou Securities Regulatory Bureau [1] - Guizhou Bailing's financial reports for 2019, 2020, 2021, and 2023 contained false records, resulting in a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [1] - The company will face a fine of 10 million yuan and warnings for its financial misconduct, while 10 responsible individuals, including Jiang Wei, will be fined a total of 15.6 million yuan and face a 10-year market ban [1] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and protect investor rights [2] - Guizhou Bailing is a pharmaceutical company involved in the research, production, and sales of traditional medicine, with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup [2]

Core Viewpoint - The recent administrative penalty imposed on Nuotai Biopharmaceuticals (688076.SH) by the China Securities Regulatory Commission (CSRC) highlights serious violations of financial reporting and disclosure regulations, leading to a significant loss of trust in the company within the capital market [2][3]. Group 1: Violations and Penalties - Nuotai Biopharmaceuticals was penalized for two main violations: false records in the 2021 annual report and fabrication of significant false content in public offering documents, resulting in a total fine of 76.2 million yuan [2][3]. - The CSRC's decision includes a warning and a fine of 47.4 million yuan for the company, along with fines totaling 28.8 million yuan for six senior executives, including the actual controllers Zhao Dezhong and Zhao Deyi [2][3]. - The Shanghai Stock Exchange has also imposed disciplinary measures, prohibiting Nuotai from submitting any issuance or listing application documents for five years, and barring Zhao Dezhong from holding any senior positions in listed companies for three years [2][7]. Group 2: Financial Performance and Fraudulent Activities - Despite a strong growth trajectory, with projected revenues of 651 million yuan, 1.034 billion yuan, and 1.625 billion yuan from 2022 to 2024, Nuotai engaged in fraudulent activities during its first year of listing [3][4]. - The company falsely recorded 30 million yuan in revenue from a technology transfer agreement with Zhejiang Huabei Pharmaceutical, which lacked commercial substance, leading to an inflated profit margin of 20.64% in its annual report [4][5]. - Nuotai's subsequent issuance of convertible bonds involved fraudulent financial data, further violating capital market rules and resulting in significant penalties [5][6]. Group 3: Market Impact and Industry Implications - The penalties and restrictions will severely limit Nuotai's ability to raise funds, which is critical for research and development in the highly capital-intensive pharmaceutical industry [7][8]. - The company's stock price has already experienced volatility due to regulatory scrutiny, and the ongoing trust issues may hinder its market expansion and partnerships, especially in the competitive GLP-1 market [7][8]. - The case serves as a warning for the entire pharmaceutical industry, with a reported 47% increase in regulatory penalties for A-share pharmaceutical companies from 2023 to 2025, emphasizing the need for strict compliance [8].

12月19日晚，贵州百灵（002424）发布公告称，公司及相关当事人于当日收到贵州证监局出具的《行政 处罚事先告知书》。经查明，2019年至2021年，贵州百灵少计销售费用，累计虚增利润65472.60万元； 2023年，公司多计销售费用，虚减利润45941.10万元。 基于此，监管部门拟对贵州百灵及10名在职"董高"人员给予警告，并合计罚款2560万元。 其中，贵州百灵与公司董事长姜伟均为顶格处罚，前者拟罚款1000万元，后者拟罚款500万元。而且， 拟对姜伟采取10年证券市场禁入措施。 一份高质量的财务报告，既是投资者挖掘上市公司价值的重要指南，也是构筑资本市场的信任基石。业 内人士表示，贵州百灵一案再次表明，无论是"硬造假"，还是"软造假"，监管的态度一以贯之：打假保 真，给投资者一个真实的上市公司；造假必重罚，严重造假要退市。 贵州百灵同时发布公告称，公司股票自12月22日开市起停牌一天，并于12月23日开市起复牌。公司股票 在12月23日开市起被实施其他风险警示，公司股票简称由"贵州百灵"变更为"ST百灵"，股票交易日涨跌 幅限制5%。 违反会计准则 导致公司多年财务数据失真 监管认为，在2019年 ...

12月19日晚，贵州百灵发布公告称，公司及相关当事人于当日收到贵州证监局出具的《行政处罚事先告 知书》。经查明，2019年至2021年，贵州百灵少计销售费用，累计虚增利润65472.60万元；2023年，公 司多计销售费用，虚减利润45941.10万元。 基于此，监管部门拟对贵州百灵及10名在职"董高"人员给予警告，并合计罚款2560万元。 其中，贵州百灵与公司董事长姜伟均为顶格处罚，前者拟罚款1000万元，后者拟罚款500万元。而且， 拟对姜伟采取10年证券市场禁入措施。 根据《行政处罚事先告知书》，贵州百灵销售费用核算问题造成的利润影响如下： 2019年少计销售费用35012.49万元，多计利润35012.49 万元，占当期报告记载利润总额(绝对值)的 95.73%； 2020年少计销售费用24080.95万元，多计利润24080.95 万元，占当期报告记载利润总额(绝对值)的 115.35%； 2021年少计销售费用6379.16万元，多计利润6379.16万元，占当期报告记载利润总额(绝对值)的 45.04%； 一份高质量的财务报告，既是投资者挖掘上市公司价值的重要指南，也是构筑资本市场的信任基石。业 ...

Group 1 - Guizhou Baikang (002424) has been penalized by the Guizhou Securities Regulatory Bureau for financial fraud, with the company and related parties receiving an administrative penalty notice [2] - The company reported false financial data in its annual reports for 2019, 2020, 2021, and 2023, leading to a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [2] - The company's stock will be suspended for one day starting December 22 and will resume trading on December 23 under the risk warning label "ST Baikang" [2] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and deterrence [3] - The bureau focuses on key individuals such as actual controllers, major shareholders, directors, and senior executives, as well as intermediary institutions [3] - Guizhou Baikang is a pharmaceutical company involved in the research, production, and sales of苗药 (苗药) and has several key products contributing to its profits [3]

贵州证监局网站12月19日消息，近日，中国证券监督管理委员会贵州监管局对贵州百灵企业集团制药股份有限公司（贵州百灵）涉嫌定期报告财务数据存在 虚假记载作出行政处罚及市场禁入事先告知。 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至2021年期间少计销售费用，累计虚增利润6.55亿元， 2023年多计销售费用，虚减利润4.59亿元。对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正，给予警告，处 以1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证券市场禁入措施。 财务造假是严重破坏市场"三公"原则,侵害投资者合法权益的毒瘤。贵州证监局将坚决贯彻证监会党委的各项决策部署,着力提升监管执法的有效性和震慑力, 坚持对财务造假"零容忍"打击的鲜明立场,聚焦打大、打恶、打重点,紧盯实控人、控股股东、董事、高管等"关键少数"和中介机构"看门人",严格执法、秉公 执法,坚决做到监管"长牙带刺"、有棱有角,以有力监管执法护航贵州资本市场行稳致远。 公司还公告称，公司及相关当事人分别收到贵州证监局 ...